EUVIMEDScopri EUVIMED
Crossref

LaSOM 335, active against bladder cancer cells, interferes with Let‐60 ( h Ras ) and reduces CD 73 expression/activity

Luciano Porto Kagami iD, Itamar Luís Gonçalves iD, Álisson Coldebella da Silva, Aline Castro Silva, Gustavo Machado das Neves iD, Gabriela Göethel, Adriano Spillere, Maitê Roxo Dos Santos, Fabrício Figueiró iD, Solange Cristina Garcia iD, Daiana Silva Ávila iD, Ana Maria Oliveira Battastini iD and 1 more

Chemical Biology & Drug Design · 2023

DOI: 10.1111/cbdd.14273 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2023. Written by Luciano Porto Kagami and 12 co-authors. Institution: Laboratório de Síntese Orgânica Medicinal - LaSOM®, Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal …. Major MEDLINE topics: Genes, ras, Urinary Bladder Neoplasms, Biphenyl Compounds, Pyrimidinones. Cited 4 times so far (Crossref); 35 references. Funded by: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Bladder cancer is the fourth most common malignancy in men. It can present along the entire continuum of severity, from mild to well‐differentiated disease to extremely malignant tumors with low survival rates. Human RAS genes are the most frequently mutated oncogenes in human cancers, and the critical role of aberrant Ras protein function in carcinogenesis is well established. Therefore, considerable efforts have been devoted to the development of anti‐Ras inhibitors for cancer treatment. This study presents the biphenyl dihydropyrimidinone LaSOM 335 with high activity against T24 bladder cancer cells (IC 50 = 10.73 ± 0.53 μM) and selectivity of cytotoxicity for this cancer cell line compared to two non‐cancer cell lines investigated. Furthermore, we also show that this compound reduced vulvar development in the mutant let ‐60 gene of Caenorhabditis elegans . Let ‐60 is a homolog of the mammalian Ras gene. In addition, we observed that LaSOM 335 inhibits the enzymatic activity of CD73 and decreases CD73 expression. Possibly, this expression decrease is due to downstream EGFR signaling via the Ras–Raf–ERK pathway, that directly regulates CD73 expression via ERK1/2. Evidence suggests that non‐immunomodulating functions of CD73 play an equally important role for cancer cell survival, progression, and migration. Regarding we also notice that LaSOM 335 was safe in the in vivo model of C. elegans . The set of these findings makes this biphenyl dihydropyrimidinone a promising candidate for further investigations in the bladder cancer field.

Subjects

MeSH terms (MEDLINE)

Genes, rasUrinary Bladder NeoplasmsBiphenyl CompoundsPyrimidinonesAnimalsHumansMale5'-NucleotidaseCaenorhabditis elegansCell Line, Tumor

Author keywords

Caenorhabditis elegansCD73LaSOM 335T24 bladder cancer cellsdihydropyrimidinonesecto-5′-nucleotidase

Substances

5'-NucleotidaseBiphenyl CompoundsPyrimidinonesbiphenylbiphenyl-dihydropyrimidinone

Authors and institutions

  • Laboratório de Síntese Orgânica Medicinal - LaSOM®, Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Faculdade de Medicina, Universidade Regional Integrada do Alto Uruguai e das Missões-URI, Erechim, Brazil.
  • Departamento de Bioquímica, Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Graduation Program in Biochemistry, Laboratory of Biochemistry and Toxicology in Caenorhabditis elegans, Federal University of Pampa, Uruguaiana, Brazil.
  • Laboratory of Toxicology (LATOX), Department of Analyses, Programa de Pós-Graduação em Ciências Farmacêuticas, Faculty of Pharmacy, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

ORCID profiles: Luciano Porto Kagami, Itamar Luís Gonçalves, Gustavo Machado das Neves, Fabrício Figueiró, Solange Cristina Garcia, Daiana Silva Ávila, Ana Maria Oliveira Battastini, Vera Lucia Eifler-Lima

Funding

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Cite

APA

Kagami, L. P., Gonçalves, I. L., da Silva, Á. C., Silva, A. C., das Neves, G. M., Göethel, G., Spillere, A., Dos Santos, M. R., Figueiró, F., Garcia, S. C., Ávila, D. S., Battastini, A. M. O., & Eifler-Lima, V. L. (2023). LaSOM 335, active against bladder cancer cells, interferes with Let‐60 ( h Ras ) and reduces CD 73 expression/activity. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14273

Vancouver

Kagami LP, Gonçalves IL, da Silva ÁC, Silva AC, das Neves GM, Göethel G, et al. LaSOM 335, active against bladder cancer cells, interferes with Let‐60 ( h Ras ) and reduces CD 73 expression/activity. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14273

BibTeX
@article{Kagami2023,
  author = {Kagami, Luciano Porto and Gonçalves, Itamar Luís and da Silva, Álisson Coldebella and Silva, Aline Castro and das Neves, Gustavo Machado and Göethel, Gabriela and Spillere, Adriano and Dos Santos, Maitê Roxo and Figueiró, Fabrício and Garcia, Solange Cristina and Ávila, Daiana Silva and Battastini, Ana Maria Oliveira and Eifler-Lima, Vera Lucia},
  title = {LaSOM 335, active against bladder cancer cells, interferes with Let‐60 ( h Ras ) and reduces CD 73 expression/activity},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  doi = {10.1111/cbdd.14273}
}
Start for free →